Cargando…

No evidence for neuronal damage or astrocytic activation in cerebrospinal fluid of Neuro-COVID-19 patients with long-term persistent headache

Headache is one of the most common neurological manifestations of COVID-19, but it is unclear whether chronic headache as a symptom of Post-COVID-19 is associated with ongoing CNS damage. We compared cerebrospinal fluid (CSF) levels of markers of CNS damage and inflammation in Post-COVID-19 patients...

Descripción completa

Detalles Bibliográficos
Autores principales: de Boni, Laura, Odainic, Alexandru, Gancarczyk, Natalie, Kaluza, Luisa, Strassburg, Christian P., Kersting, Xenia A. K., Wüllner, Ullrich, Schmidt, Susanne V., Petzold, Gabor C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10536703/
https://www.ncbi.nlm.nih.gov/pubmed/37759276
http://dx.doi.org/10.1186/s42466-023-00277-1
_version_ 1785112933743722496
author de Boni, Laura
Odainic, Alexandru
Gancarczyk, Natalie
Kaluza, Luisa
Strassburg, Christian P.
Kersting, Xenia A. K.
Wüllner, Ullrich
Schmidt, Susanne V.
Petzold, Gabor C.
author_facet de Boni, Laura
Odainic, Alexandru
Gancarczyk, Natalie
Kaluza, Luisa
Strassburg, Christian P.
Kersting, Xenia A. K.
Wüllner, Ullrich
Schmidt, Susanne V.
Petzold, Gabor C.
author_sort de Boni, Laura
collection PubMed
description Headache is one of the most common neurological manifestations of COVID-19, but it is unclear whether chronic headache as a symptom of Post-COVID-19 is associated with ongoing CNS damage. We compared cerebrospinal fluid (CSF) levels of markers of CNS damage and inflammation in Post-COVID-19 patients with persistent headache to hospitalized acute COVID-19 patients with neurological symptoms and to non-COVID-19 disease-controls. CSF levels of neurofilament light chain, Ubiquitin carboxyl-terminal hydrolase L1 and Tau were similar in patients with persistent headache in post-COVID-19 compared to acute COVID-19 patients and all control groups. Levels of glial fibrillary astrocytic protein were lower in patients with persistent headache in post-COVID-19 compared to some control groups of patients with neurological disease. Therefore, our pilot study of CSF markers indicates that persistent post-COVID-19 headache is not a sign of underlying neuronal damage or glial activation. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s42466-023-00277-1.
format Online
Article
Text
id pubmed-10536703
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-105367032023-09-29 No evidence for neuronal damage or astrocytic activation in cerebrospinal fluid of Neuro-COVID-19 patients with long-term persistent headache de Boni, Laura Odainic, Alexandru Gancarczyk, Natalie Kaluza, Luisa Strassburg, Christian P. Kersting, Xenia A. K. Wüllner, Ullrich Schmidt, Susanne V. Petzold, Gabor C. Neurol Res Pract Letter to the Editor Headache is one of the most common neurological manifestations of COVID-19, but it is unclear whether chronic headache as a symptom of Post-COVID-19 is associated with ongoing CNS damage. We compared cerebrospinal fluid (CSF) levels of markers of CNS damage and inflammation in Post-COVID-19 patients with persistent headache to hospitalized acute COVID-19 patients with neurological symptoms and to non-COVID-19 disease-controls. CSF levels of neurofilament light chain, Ubiquitin carboxyl-terminal hydrolase L1 and Tau were similar in patients with persistent headache in post-COVID-19 compared to acute COVID-19 patients and all control groups. Levels of glial fibrillary astrocytic protein were lower in patients with persistent headache in post-COVID-19 compared to some control groups of patients with neurological disease. Therefore, our pilot study of CSF markers indicates that persistent post-COVID-19 headache is not a sign of underlying neuronal damage or glial activation. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s42466-023-00277-1. BioMed Central 2023-09-28 /pmc/articles/PMC10536703/ /pubmed/37759276 http://dx.doi.org/10.1186/s42466-023-00277-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Letter to the Editor
de Boni, Laura
Odainic, Alexandru
Gancarczyk, Natalie
Kaluza, Luisa
Strassburg, Christian P.
Kersting, Xenia A. K.
Wüllner, Ullrich
Schmidt, Susanne V.
Petzold, Gabor C.
No evidence for neuronal damage or astrocytic activation in cerebrospinal fluid of Neuro-COVID-19 patients with long-term persistent headache
title No evidence for neuronal damage or astrocytic activation in cerebrospinal fluid of Neuro-COVID-19 patients with long-term persistent headache
title_full No evidence for neuronal damage or astrocytic activation in cerebrospinal fluid of Neuro-COVID-19 patients with long-term persistent headache
title_fullStr No evidence for neuronal damage or astrocytic activation in cerebrospinal fluid of Neuro-COVID-19 patients with long-term persistent headache
title_full_unstemmed No evidence for neuronal damage or astrocytic activation in cerebrospinal fluid of Neuro-COVID-19 patients with long-term persistent headache
title_short No evidence for neuronal damage or astrocytic activation in cerebrospinal fluid of Neuro-COVID-19 patients with long-term persistent headache
title_sort no evidence for neuronal damage or astrocytic activation in cerebrospinal fluid of neuro-covid-19 patients with long-term persistent headache
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10536703/
https://www.ncbi.nlm.nih.gov/pubmed/37759276
http://dx.doi.org/10.1186/s42466-023-00277-1
work_keys_str_mv AT debonilaura noevidenceforneuronaldamageorastrocyticactivationincerebrospinalfluidofneurocovid19patientswithlongtermpersistentheadache
AT odainicalexandru noevidenceforneuronaldamageorastrocyticactivationincerebrospinalfluidofneurocovid19patientswithlongtermpersistentheadache
AT gancarczyknatalie noevidenceforneuronaldamageorastrocyticactivationincerebrospinalfluidofneurocovid19patientswithlongtermpersistentheadache
AT kaluzaluisa noevidenceforneuronaldamageorastrocyticactivationincerebrospinalfluidofneurocovid19patientswithlongtermpersistentheadache
AT strassburgchristianp noevidenceforneuronaldamageorastrocyticactivationincerebrospinalfluidofneurocovid19patientswithlongtermpersistentheadache
AT kerstingxeniaak noevidenceforneuronaldamageorastrocyticactivationincerebrospinalfluidofneurocovid19patientswithlongtermpersistentheadache
AT wullnerullrich noevidenceforneuronaldamageorastrocyticactivationincerebrospinalfluidofneurocovid19patientswithlongtermpersistentheadache
AT schmidtsusannev noevidenceforneuronaldamageorastrocyticactivationincerebrospinalfluidofneurocovid19patientswithlongtermpersistentheadache
AT petzoldgaborc noevidenceforneuronaldamageorastrocyticactivationincerebrospinalfluidofneurocovid19patientswithlongtermpersistentheadache